针对杆菌的向治疗的响应pH的脂质体
Huihua Dong1, Aixing Guan2,3, Shixian Yang2,3
1Guangxi Technology Innovation Cooperation Base of Prevention and Control Pathogenic Microbes with Drug Resistance, Youjiang Medical University for Nationalities, Baise, 533000, China.
Materials today. Bio
|September 2, 2025
概括
新的脂质体封装素 (LUT) 纳米颗粒,H-L-NP,显示出增强的溶解性和强大的抗菌活性对抗耐药Helicobacter pylori (H. pylori). 这种有针对性的治疗提供了传统治疗的有希望的替代方案.
科学领域:
- 药理学
- 纳米技术
- 微生物学
背景情况:
- 增加Helicobacter pylori (H. pylori) 的抗生素耐药性需要新的治疗策略.
- 素 (LUT) 具有抗菌性质,但其水溶性较差,有效性不足.
- 目前的治疗方法面临诸多挑战,包括副作用和耐药性的发展.
研究的目的:
- 增强黄素对H. pylori的水溶性和抗菌功效.
- 为改善H. pylori治疗开发有针对性的和对酸反应的纳米颗粒.
- 与现有疗法相比,评估H-L-NP的体外和体内性能.
主要方法:
- 在脂质体内封装LUT.
- 用酸盐四级盐涂层脂质体,以产生H-L-NP.
- 对溶解度,最小抑制度 (MIC) 和体内疗效的评估.
- 对肠道微生物群多样性的安全性和影响的评估.
主要成果:
- 与LUT相比,H-L-NP显著提高了溶解度,MIC降低了1024倍.
- 在抗药性H. pylori菌株中,H-L-NP是有效的.
- 与标准的三重疗法相比,H-L-NP体内治疗显示出更好的结果.
- H-L-NP 显示出高安全性,特异性,并保持了肠道微生物群的多样性.
结论:
- H-L-NP代表了抗H. pylori疗法的重大进展,克服了LUT的局限性.
- H-L-NP的向性,对酸的反应性提高了疗效,并最大限度地减少了非向性效应.
- 这种新型配方显示出预防H. pylori耐药性的潜力,并提供了有前途的治疗方法.
相关概念视频
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
546
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
546
01:26Peptic Ulcer Disease IV: Management
145
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
145
01:13Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
525
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
525
01:28Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
569
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
569